Smith & Nephew Plc - Director/PDMR Shareholding
SMITH & NEPHEW PLC
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This announcement is made in accordance with the
On
1. VESTING OF 2023 PERFORMANCE SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLANS 2020 AND 2010.
The awards vested on
The following relates to individuals included in the below notification:
|
Reason for the notification |
|
|
Initial notification /Amendment |
Initial notification |
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
Name |
Smith & Nephew plc |
|
LEI |
213800ZTMDN8S67S1H61 |
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
Description of the financial instrument, type of instrument |
Smith & Nephew plc ordinary shares of
|
|
Identification code |
ISIN: GB0009223206 |
|
Nature of the transaction |
Vesting of awards under the Smith & Nephew Global Share Plans 2020 and 2010 followed by the sale of shares to cover the relevant tax liabilities. |
|
Date of Transaction |
|
|
Place of Transaction |
London Stock Exchange (XLON) |
|
Name (Position) |
Status |
Price (£) |
Volume |
Aggregated information |
|
(Chief Executive Officer) |
Director |
11.938637 |
109, 650 (of which 44,994 were sold and 64, 656 retained) |
N/A Single Transaction |
|
(Group General Counsel and Company Secretary) |
PDMR |
11.938637 |
24,047 (of which 11,342 were sold and 12,705 retained) |
N/A Single Transaction |
|
(President Global Operations) |
PDMR |
11.938637 |
31,789 (of which 9,289 were sold and 22,500 retained) |
N/A Single Transaction |
|
(President, Orthopaedics) |
PDMR |
11.938637 |
14,565 (of which 3,691 were sold and 10,874 retained) |
N/A Single Transaction |
|
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer) |
PDMR |
11.938637 |
32,504 (of which 10,572 were sold and 21,932 retained) |
N/A Single Transaction |
|
(Chief HR Officer) |
PDMR |
11.938637 |
39,778 (of which 16,023 were sold and 23,755 retained) |
N/A Single Transaction |
|
(President Research & Development, ENT and Emerging Markets) |
PDMR |
11.938637 |
38,697 (of which 15,534 were sold and 23,163 retained) |
N/A Single Transaction |
|
(Chief Compliance Officer)
|
PDMR |
11.938637 |
9, 403 (of which 4, 307 were sold and 5 096 retained) |
N/A Single Transaction |
|
(President Sports Medicine) |
PDMR |
11.938637 |
56,942 (of which 19,961 were sold and 36,981 retained) |
N/A Single Transaction |
|
(President, Advanced Wound Management and Global Commercial Operations) |
PDMR |
11.938637 |
60,390 (of which 16,309 were sold and 44,081 retained) |
N/A Single Transaction |
All figures in these columns are stated to 6 decimal places where applicable.
2. VESTING OF DEFERRED BONUS SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2020
The awards vested on
The following relates to individuals included in the below notification:
|
Reason for the notification |
|
|
Initial notification /Amendment |
Initial notification |
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
Name |
Smith & Nephew plc |
|
LEI |
213800ZTMDN8S67S1H61 |
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
Description of the financial instrument, type of instrument
|
Smith & Nephew plc ordinary shares of
|
|
Identification code |
ISIN: GB0009223206 |
|
Nature of the transaction |
Vesting of Deferred Bonus Share awards under the Smith & Nephew Global Share Plan 2020 followed by the sale of shares to cover the relevant tax liabilities. |
|
Date of Transaction |
|
|
Place of Transaction |
London Stock Exchange (XLON) |
|
Name (Position) |
Status |
Price (£) |
Volume |
Aggregated information |
|
(Chief Executive Officer) |
Director |
11.938637 |
27,739 (of which 11,383 were sold and 16,356 retained) |
N/A Single Transaction |
|
(Group General Counsel and Company Secretary) |
PDMR |
11.938637 |
8,793 (of which 4,148 were sold and 4,645 retained) |
N/A Single Transaction |
|
(President Global Operations) |
PDMR |
11.938637 |
9,099 (of which 3,458 were sold and 5,641 retained) |
N/A Single Transaction |
|
(President, Orthopaedics) |
PDMR |
11.938637 |
5,310 (of which 1,401 were sold and 3,909 retained) |
N/A Single Transaction |
|
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer) |
PDMR |
11.938637 |
9,963 (of which 4,002 were sold and 5,961 retained) |
N/A Single Transaction |
|
(Chief HR Officer) |
PDMR |
11.938637 |
13,214 (of which 5,325 were sold and 7,889 retained) |
N/A Single Transaction |
|
(President Research & Development, ENT and Emerging Markets) |
PDMR |
11.938637 |
12,619 (of which 5,065 were sold and 7,554 retained) |
N/A Single Transaction |
|
(Chief Compliance Officer) |
PDMR |
11.938637 |
5,550 (of which 2,604 were sold and 2,946 retained.) |
N/A Single Transaction |
|
(President Sports Medicine) |
PDMR |
11.938637 |
14,045 (of which 5,147 were sold and 8,898 retained) |
N/A Single Transaction |
|
|
PDMR |
11.938637 |
9,671 (of which 3,445 were sold and 6,226 retained) |
N/A Single Transaction |
All figures in these columns are stated to 6 decimal places where applicable.
3. PARTIAL VESTING OF 2025 RESTRICTED SHARE AWARDS MADE UNDER THE RESTRICTED SHARE PLAN 2024
The awards vested on
The following relates to individuals included in the below notification:
|
Reason for the notification |
|
|
Initial notification /Amendment |
Initial notification |
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
Name |
Smith & Nephew plc |
|
LEI |
213800ZTMDN8S67S1H61 |
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
Description of the financial instrument, type of instrument
|
Smith & Nephew plc ordinary shares of
|
|
Identification code |
ISIN: GB0009223206 |
|
Nature of the transaction |
Vesting of Restricted Share awards under the Smith & Nephew Restricted Share Plan 2024 followed by the sale of shares to cover the relevant tax liabilities. |
|
Date of Transaction |
|
|
Place of Transaction |
London Stock Exchange (XLON) |
|
Name (Position) |
Status |
Price (£) |
Volume |
Aggregated information |
|
(Chief Executive Officer) |
Director |
11.938637 |
45,220 (of which 18,587 were sold and 26,633 retained) |
N/A Single Transaction |
|
(Chief Financial Officer) |
Director |
11.938637 |
13 902 (of which 8, 663 were sold and 5 239 retained) |
N/A Single Transaction |
|
(Group General Counsel and Company Secretary) |
PDMR |
11.938637 |
7,942 (of which 3,746 were sold and 4,196 retained) |
N/A Single Transaction |
|
(President, Global Operations) |
PDMR |
11.938637 |
7,732 (of which 3,387 were sold and 4,345 retained) |
N/A Single Transaction |
|
(President, Orthopaedics) |
PDMR |
11.938637 |
13,159 (of which 3,216 were sold and 9,943 retained) |
N/A Single Transaction |
|
Mizanu Kebede (Chief Quality & Regulatory Affairs Officer) |
PDMR |
11.938637 |
8,091 (of which 3,764 were sold and 4,327 retained) |
N/A Single Transaction |
|
(Chief HR Officer) |
PDMR |
11.938637 |
13,120 (of which 5,309 were sold and 7,811 retained) |
N/A Single Transaction |
|
(President Research & Development, ENT and Emerging Markets) |
PDMR |
11.938637 |
10,661 (of which 4,280 were sold and 6,381 retained) |
N/A Single Transaction |
|
(Chief Compliance Officer) |
PDMR |
11.938637 |
3,441 (of which 1,623 were sold and 1,818 retained) |
N/A Single Transaction |
|
(President Sports Medicine) |
PDMR |
11.938637 |
15,437 (of which 6,555 were sold and 8,882 retained) |
N/A Single Transaction |
|
|
PDMR |
11.938637 |
16,161 (of which 6,383 were sold and 9,778 retained) |
N/A Single Transaction |
All figures in these columns are stated to 6 decimal places where applicable.
Group Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477100
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).
Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.
Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.
All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.
This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.
Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.
This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.
FOR OUR FULL DISCLAIMER CLICK HERE